Dendritic Cell Vaccine Inhibits Tumor Progression in Preclinical Liver Cancer Model

Saronic Biotechnology, Inc. announced publication of preclinical data of autologous dendritic cell (DC) vaccine treatment in a murine model for hepatocellular carcinoma (HCC) indicating inhibited tumor progression.
According to the news:

The preclinical DC vaccine results, accepted for publication in the Annals of Surgical Oncology, describe treatment outcomes in an orthotopic murine model of HCC treated by administration of DC vaccine loaded with tumor cell lysate. Results demonstrated significantly increased survival: 90% survival rate for DC vaccine-treated mice versus 5% survival rate for untreated mice at day 60. Noninvasive bioluminescence imaging was utilized to evaluate the effect of DC vaccine on tumor growth, and indicated visible tumor regression in DC vaccine-treated mice. DC vaccine treatment also decreased levels of immunosuppressive Foxp3+ regulatory T cells in the tumor microenvironment. Foxp3 has been correlated with poor overall survival among patients with resectable hepatocellular carcinoma¹

Click here to view the full press release.